• Home
  • Pharmacy Medical Policy Updates

Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs will be updated March 1, 2024:

Effective April 1, 2024:

  • Reblozyl
  • Rapid to Intermediate Acting Insulin
  • Lysosomal Storage Disorders
  • Substrate Reduction Therapy
  • Daybue
  • Copay Waiver
  • SA Oncology
  • Oxybate
  • Wakix
  • Sunosi
  • Urea Cycle Disorders
  • Synagis
  • Vascepa
  • Antifungals
  • Pseudobulbar Affect
  • Acute Hepatic Porphyria
  • Oxlumo
  • Xdemvy
  • Zilbrysq
  • Syfovre (MRx)

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization

If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.

Institutional Providers
Professional Providers